American Heart Journal
Volume 157, Issue 3 , Pages 399-401 , March 2009

The pain and the gain of treating patients with acute coronary syndromes—can the two be separated?

  • Sorin J. Brener, MD

      Affiliations

    • New York Methodist Hospital, Brooklyn, NY
    • Corresponding Author InformationReprint requests: Sorin J. Brener, MD, FACC, NY Methodist Hospital, New York, NY 11215.
    • ,
  • Deepak L. Bhatt, MD, MPH

      Affiliations

    • VA Boston Healthcare System and Brigham and Women's Hospital, Boston, MA

Received 17 November 2008 ,Accepted 19 November 2008.

References 

  1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–e146
  2. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol. 2007;49:1362–1368
  3. Joyner CD, Peters RJG, Afzal R, et al. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. Am Heart J. 2009;157:502–508
  4. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163:2345–2353
  5. Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol. 2008;51:690–697
  6. Budaj A, Eikelboom JW, Mehta SR, et al. Improving clinical outcomes by reducing bleeding in patients with non–ST-elevation acute coronary syndromes. Eur Heart J [Electronic Publication 2008 Aug 18].
  7. Stone GW, Ware JH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY Trial. JAMA. 2007;298:2497–2506
  8. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464–1476
  9. Giugliano RP, Giraldez RR, Morrow DA, et al. The relative contribution of clinical factors, treatments bleeding and CV complication to mortality in 20,323 patients receiving fibrinolysis for STEMI. J Am Coll Cardiol. 2008;51:A209
  10. Spencer FA, Moscucci M, Granger CB, et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?. Circulation. 2007;116:2793–2801
  11. Bhatt DL. Intensifying platelet inhibition—navigating between Scylla and Charybdis. N Engl J Med. 2007;357:2078–2081

PII: S0002-8703(08)01030-2

doi: 10.1016/j.ahj.2008.11.012

American Heart Journal
Volume 157, Issue 3 , Pages 399-401 , March 2009

Article Tools

* Image Usage & Resolution